Shelter Pharma (543963) Q2 24/25 earnings summary

Executive summary

• Standalone unaudited financial results for the half year ended September 30, 2024, were approved by the board on October 30, 2024.

• Independent auditor's review found no material misstatements or non-compliance in the financial statements.

Financial highlights

• Revenue from operations for the half year ended September 30, 2024, was ₹2,405.67 lakhs, up from ₹1,931.20 lakhs in the same period last year.

• Net profit for the half year was ₹353.64 lakhs, compared to ₹310.14 lakhs year-over-year.

• Basic and diluted EPS for the half year stood at ₹3.06, up from ₹2.68 in the prior year period.

• Total assets as of September 30, 2024, were ₹4,297.87 lakhs, compared to ₹3,791.48 lakhs as of March 31, 2024.

• Cash and cash equivalents increased to ₹599.77 lakhs from ₹503.97 lakhs at the previous year-end.

Outlook and guidance

• No forward-looking statements or specific guidance provided in the reviewed period.